-
2
-
-
0033105537
-
Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
-
Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93: 1658-1667.
-
(1999)
Blood
, vol.93
, pp. 1658-1667
-
-
Damiano, J.S.1
Cress, A.E.2
Hazlehurst, L.A.3
Shtil, A.A.4
Dalton, W.S.5
-
3
-
-
0034618384
-
Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)
-
Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000; 19: 4319-4327.
-
(2000)
Oncogene
, vol.19
, pp. 4319-4327
-
-
Hazlehurst, L.A.1
Damiano, J.S.2
Buyuksal, I.3
Pledger, W.J.4
Dalton, W.S.5
-
4
-
-
84905825111
-
The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies
-
Shain KH, Tao J. The B-cell receptor orchestrates environment-mediated lymphoma survival and drug resistance in B-cell malignancies. Oncogene 2013; 33: 4107-4113.
-
(2013)
Oncogene
, vol.33
, pp. 4107-4113
-
-
Shain, K.H.1
Tao, J.2
-
5
-
-
84875174768
-
The role of tumour-stromal interactions in modifying drug response: Challenges and opportunities
-
McMillin DW, Negri JM, Mitsiades CS. The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 2013; 12: 217-228.
-
(2013)
Nat Rev Drug Discov
, vol.12
, pp. 217-228
-
-
McMillin, D.W.1
Negri, J.M.2
Mitsiades, C.S.3
-
6
-
-
84907200622
-
Entering the era of targeted therapy for chronic lymphocytic leukemia: Impact on the practicing clinician
-
Byrd JC, Jones JJ, Woyach JA, Johnson AJ, Flynn JM. Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician. J Clin Oncol. 2014; 32: 3039-3047.
-
(2014)
J Clin Oncol.
, vol.32
, pp. 3039-3047
-
-
Byrd, J.C.1
Jones, J.J.2
Woyach, J.A.3
Johnson, A.J.4
Flynn, J.M.5
-
7
-
-
69249087671
-
Environment-mediated drug resistance: A major contributor to minimal residual disease
-
Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev 2009; 9: 665-674.
-
(2009)
Nat Rev
, vol.9
, pp. 665-674
-
-
Meads, M.B.1
Gatenby, R.A.2
Dalton, W.S.3
-
8
-
-
8644255150
-
Prognosis in follicular lymphoma-it's in the microenvironment
-
Kuppers R. Prognosis in follicular lymphoma-it's in the microenvironment. N Engl J Med 2004; 351: 2152-2153.
-
(2004)
N Engl J Med
, vol.351
, pp. 2152-2153
-
-
Kuppers, R.1
-
9
-
-
70350734809
-
The microenvironment in mature B-cell malignancies: A target for new treatment strategies
-
Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367-3375.
-
(2009)
Blood
, vol.114
, pp. 3367-3375
-
-
Burger, J.A.1
Ghia, P.2
Rosenwald, A.3
Caligaris-Cappio, F.4
-
10
-
-
77950542260
-
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity
-
McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med 2010; 16: 483-489.
-
(2010)
Nat Med
, vol.16
, pp. 483-489
-
-
McMillin, D.W.1
Delmore, J.2
Weisberg, E.3
Negri, J.M.4
Geer, D.C.5
Klippel, S.6
-
11
-
-
37549015263
-
Germinal centres: Role in B-cell physiology and malignancy
-
Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8: 22-33.
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 22-33
-
-
Klein, U.1
Dalla-Favera, R.2
-
12
-
-
84875185728
-
Targeting pathological B cell receptor signalling in lymphoid malignancies
-
Young RM, Staudt LM. Targeting pathological B cell receptor signalling in lymphoid malignancies. Nat Rev Drug Discov 2013; 12: 229-243.
-
(2013)
Nat Rev Drug Discov
, vol.12
, pp. 229-243
-
-
Young, R.M.1
Staudt, L.M.2
-
13
-
-
42449114035
-
Multiple myeloma
-
Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008; 111: 2962-2972.
-
(2008)
Blood
, vol.111
, pp. 2962-2972
-
-
Kyle, R.A.1
Rajkumar, S.V.2
-
14
-
-
84858590826
-
Accessories to the crime: Functions of cells recruited to the tumor microenvironment
-
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
-
(2012)
Cancer Cell
, vol.21
, pp. 309-322
-
-
Hanahan, D.1
Coussens, L.M.2
-
15
-
-
84870544677
-
Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing
-
Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44: 1316-1320.
-
(2012)
Nat Genet
, vol.44
, pp. 1316-1320
-
-
Richter, J.1
Schlesner, M.2
Hoffmann, S.3
Kreuz, M.4
Leich, E.5
Burkhardt, B.6
-
16
-
-
58149345546
-
Co-evolution of tumor cells and their microenvironment
-
Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009; 25: 30-38.
-
(2009)
Trends Genet
, vol.25
, pp. 30-38
-
-
Polyak, K.1
Haviv, I.2
Campbell, I.G.3
-
17
-
-
84862506605
-
Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features
-
Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features. Blood 2012; 119: 5782-5794.
-
(2012)
Blood
, vol.119
, pp. 5782-5794
-
-
Azab, A.K.1
Hu, J.2
Quang, P.3
Azab, F.4
Pitsillides, C.5
Awwad, R.6
-
18
-
-
8644252736
-
Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells
-
Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC et al. Prediction of survival in follicular lymphoma based on molecular features of tumorinfiltrating immune cells. N Engl J Med 2004; 351: 2159-2169.
-
(2004)
N Engl J Med
, vol.351
, pp. 2159-2169
-
-
Dave, S.S.1
Wright, G.2
Tan, B.3
Rosenwald, A.4
Gascoyne, R.D.5
Chan, W.C.6
-
19
-
-
0025228518
-
Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo
-
Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247: 1457-1461.
-
(1990)
Science
, vol.247
, pp. 1457-1461
-
-
Teicher, B.A.1
Herman, T.S.2
Holden, S.A.3
Wang, Y.Y.4
Pfeffer, M.R.5
Crawford, J.W.6
-
20
-
-
0032984589
-
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
-
Catlett-Falcone R, Landowski TH, Oshiro MM, Turkson J, Levitzki A, Savino R et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105-115.
-
(1999)
Immunity
, vol.10
, pp. 105-115
-
-
Catlett-Falcone, R.1
Landowski, T.H.2
Oshiro, M.M.3
Turkson, J.4
Levitzki, A.5
Savino, R.6
-
21
-
-
34948893474
-
Novel therapeutic avenues in myeloma: Changing the treatment paradigm
-
discussion 798-800
-
Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS et al. Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park, NY) 2007; 21: 785-792, discussion 798-800.
-
(2007)
Oncology (Williston Park, NY)
, vol.21
, pp. 785-792
-
-
Ghobrial, J.1
Ghobrial, I.M.2
Mitsiades, C.3
Leleu, X.4
Hatjiharissi, E.5
Moreau, A.S.6
-
22
-
-
0032588618
-
Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: Correlation with Bcl-2 and Bax
-
de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999; 13: 266-274.
-
(1999)
Leukemia
, vol.13
, pp. 266-274
-
-
De La-Fuente, M.T.1
Casanova, B.2
Garcia-Gila, M.3
Silva, A.4
Garcia-Pardo, A.5
-
23
-
-
78651285229
-
Follicular dendritic cellinduced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas
-
Lin J, Lwin T, Zhao JJ, Tam W, Choi YS, Moscinski LC et al. Follicular dendritic cellinduced microRNA-mediated upregulation of PRDM1 and downregulation of BCL-6 in non-Hodgkin's B-cell lymphomas. Leukemia 2011; 25: 145-152.
-
(2011)
Leukemia
, vol.25
, pp. 145-152
-
-
Lin, J.1
Lwin, T.2
Zhao, J.J.3
Tam, W.4
Choi, Y.S.5
Moscinski, L.C.6
-
24
-
-
34250788040
-
Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells
-
Lwin T, Hazlehurst LA, Li Z, Dessureault S, Sotomayor E, Moscinski LC et al. Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. Leukemia 2007; 21: 1521-1531.
-
(2007)
Leukemia
, vol.21
, pp. 1521-1531
-
-
Lwin, T.1
Hazlehurst, L.A.2
Li, Z.3
Dessureault, S.4
Sotomayor, E.5
Moscinski, L.C.6
-
25
-
-
59149083547
-
Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: Implications for microenvironment influence on tumor survival and proliferation
-
Shain KH, Yarde DN, Meads MB, Huang M, Jove R, Hazlehurst LA et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009; 69: 1009-1015.
-
(2009)
Cancer Res
, vol.69
, pp. 1009-1015
-
-
Shain, K.H.1
Yarde, D.N.2
Meads, M.B.3
Huang, M.4
Jove, R.5
Hazlehurst, L.A.6
-
26
-
-
84886437588
-
Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance
-
de Haart SJ, van de Donk NW, Minnema MC, Huang JH, Aarts-Riemens T, Bovenschen N et al. Accessory cells of the microenvironment protect multiple myeloma from T-cell cytotoxicity through cell adhesion-mediated immune resistance. Clin Cancer Res 2013; 19: 5591-5601.
-
(2013)
Clin Cancer Res
, vol.19
, pp. 5591-5601
-
-
De Haart, S.J.1
Van De Donk, N.W.2
Minnema, M.C.3
Huang, J.H.4
Aarts-Riemens, T.5
Bovenschen, N.6
-
27
-
-
78751549662
-
The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia
-
Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011; 117: 563-574.
-
(2011)
Blood
, vol.117
, pp. 563-574
-
-
Herishanu, Y.1
Perez-Galan, P.2
Liu, D.3
Biancotto, A.4
Pittaluga, S.5
Vire, B.6
-
28
-
-
70349237504
-
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406
-
Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009; 114: 1029-1037.
-
(2009)
Blood
, vol.114
, pp. 1029-1037
-
-
Quiroga, M.P.1
Balakrishnan, K.2
Kurtova, A.V.3
Sivina, M.4
Keating, M.J.5
Wierda, W.G.6
-
29
-
-
80053345977
-
The phosphoinositide 3 '-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
-
Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ et al. The phosphoinositide 3 '-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011; 118: 3603-3612.
-
(2011)
Blood
, vol.118
, pp. 3603-3612
-
-
Hoellenriegel, J.1
Meadows, S.A.2
Sivina, M.3
Wierda, W.G.4
Kantarjian, H.5
Keating, M.J.6
-
30
-
-
77956592891
-
PI3K/p110 {delta} is a novel therapeutic target in multiple myeloma
-
Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H et al. PI3K/p110 {delta} is a novel therapeutic target in multiple myeloma. Blood 2010; 116: 1460-1468.
-
(2010)
Blood
, vol.116
, pp. 1460-1468
-
-
Ikeda, H.1
Hideshima, T.2
Fulciniti, M.3
Perrone, G.4
Miura, N.5
Yasui, H.6
-
31
-
-
84880058104
-
In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients
-
Herman SEM, Farooqui M, Bezabhie R, Aue G, Wiestner A. In vivo effects of ibrutinib on BCR signaling, tumor cell activation and proliferation in blood and tissue-resident cells of chronic lymphocytic leukemia patients. ASH Annu Meeting Abstr 2012; 120: 185.
-
(2012)
ASH Annu Meeting Abstr
, vol.120
, pp. 185
-
-
Herman, S.E.M.1
Farooqui, M.2
Bezabhie, R.3
Aue, G.4
Wiestner, A.5
-
32
-
-
84875055944
-
The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib
-
Dasmahapatra G, Patel H, Dent P, Fisher RI, Friedberg J, Grant S. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013; 161: 43-56.
-
(2013)
Br J Haematol
, vol.161
, pp. 43-56
-
-
Dasmahapatra, G.1
Patel, H.2
Dent, P.3
Fisher, R.I.4
Friedberg, J.5
Grant, S.6
-
33
-
-
84897490051
-
How will B-cell receptor targeted therapies change future CLL therapy?
-
Jones JA, Byrd JC. How will B-cell receptor targeted therapies change future CLL therapy? Blood 2014; 123: 1455-1460.
-
(2014)
Blood
, vol.123
, pp. 1455-1460
-
-
Jones, J.A.1
Byrd, J.C.2
-
34
-
-
35748930596
-
The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies
-
vii-viii
-
Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG et al. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematology/oncology clinics of North America2007; 21: 1007-1034 vii-viii.
-
(2007)
Hematology/oncology Clinics of North America
, vol.21
, pp. 1007-1034
-
-
Mitsiades, C.S.1
McMillin, D.W.2
Klippel, S.3
Hideshima, T.4
Chauhan, D.5
Richardson, P.G.6
-
35
-
-
84887421655
-
A microenvironment mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas
-
Lwin T, Zhao X, Cheng F, Zhang X, Huang A, Shah B et al. A microenvironment mediated c-Myc/miR-548m/HDAC6 amplification loop in non-Hodgkin B cell lymphomas. J Clin Invest 2013; 123: 4612-4626.
-
(2013)
J Clin Invest
, vol.123
, pp. 4612-4626
-
-
Lwin, T.1
Zhao, X.2
Cheng, F.3
Zhang, X.4
Huang, A.5
Shah, B.6
-
36
-
-
0034596831
-
Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response
-
Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000; 192: 953-964.
-
(2000)
J Exp Med
, vol.192
, pp. 953-964
-
-
Do, R.K.1
Hatada, E.2
Lee, H.3
Tourigny, M.R.4
Hilbert, D.5
Chen-Kiang, S.6
-
37
-
-
58249102301
-
Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis
-
Lwin T, Crespo LA, Wu A, Dessureault S, Shu HB, Moscinski LC et al. Lymphoma cell adhesion-induced expression of B cell-activating factor of the TNF family in bone marrow stromal cells protects non-Hodgkin's B lymphoma cells from apoptosis. Leukemia 2009; 23: 170-177.
-
(2009)
Leukemia
, vol.23
, pp. 170-177
-
-
Lwin, T.1
Crespo, L.A.2
Wu, A.3
Dessureault, S.4
Shu, H.B.5
Moscinski, L.C.6
-
38
-
-
84864779051
-
Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and druginduced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor kappaB pathways
-
Medina DJ, Goodell L, Glod J, Gelinas C, Rabson AB, Strair RK. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and druginduced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor kappaB pathways. Haematologica 2012; 97: 1255-1263.
-
(2012)
Haematologica
, vol.97
, pp. 1255-1263
-
-
Medina, D.J.1
Goodell, L.2
Glod, J.3
Gelinas, C.4
Rabson, A.B.5
Strair, R.K.6
-
39
-
-
0029019664
-
Interleukin-6 inhibits apoptosis of malignant plasma cells
-
Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol 1995; 162: 248-255.
-
(1995)
Cell Immunol
, vol.162
, pp. 248-255
-
-
Lichtenstein, A.1
Tu, Y.2
Fady, C.3
Vescio, R.4
Berenson, J.5
-
40
-
-
84864744709
-
Context-specific roles for paracrine IL-6 in lymphomagenesis
-
Gilbert LA, Hemann MT. Context-specific roles for paracrine IL-6 in lymphomagenesis. Genes Dev 2012; 26: 1758-1768.
-
(2012)
Genes Dev
, vol.26
, pp. 1758-1768
-
-
Gilbert, L.A.1
Hemann, M.T.2
-
41
-
-
84868567076
-
Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells
-
Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 2012; 120: 3783-3792.
-
(2012)
Blood
, vol.120
, pp. 3783-3792
-
-
Zhang, L.1
Yang, J.2
Qian, J.3
Li, H.4
Romaguera, J.E.5
Kwak, L.W.6
-
42
-
-
11144240877
-
DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7
-
Li Y, Chen W, Ren J, Yu WH, Li Q, Yoshida K et al. DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-7. Cancer Biol Ther 2003; 2: 187-193.
-
(2003)
Cancer Biol Ther
, vol.2
, pp. 187-193
-
-
Li, Y.1
Chen, W.2
Ren, J.3
Yu, W.H.4
Li, Q.5
Yoshida, K.6
-
43
-
-
33746959381
-
Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma
-
Kimlinger T, Kline M, Kumar S, Lust J, Witzig T, Rajkumar SV. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma. Haematologica 2006; 91: 1033-1040.
-
(2006)
Haematologica
, vol.91
, pp. 1033-1040
-
-
Kimlinger, T.1
Kline, M.2
Kumar, S.3
Lust, J.4
Witzig, T.5
Rajkumar, S.V.6
-
44
-
-
0037262287
-
Expression and function of chemokine receptors in human multiple myeloma
-
Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia 2003; 17: 203-210.
-
(2003)
Leukemia
, vol.17
, pp. 203-210
-
-
Moller, C.1
Stromberg, T.2
Juremalm, M.3
Nilsson, K.4
Nilsson, G.5
-
45
-
-
11144358653
-
Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells
-
Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood 2004; 103: 3511-3515.
-
(2004)
Blood
, vol.103
, pp. 3511-3515
-
-
Jundt, F.1
Probsting, K.S.2
Anagnostopoulos, I.3
Muehlinghaus, G.4
Chatterjee, M.5
Mathas, S.6
-
46
-
-
84868597426
-
IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia
-
Hodge LS, Ziesmer SC, Yang ZZ, Secreto FJ, Gertz MA, Novak AJ et al. IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia. Blood 2012; 120: 3774-3782.
-
(2012)
Blood
, vol.120
, pp. 3774-3782
-
-
Hodge, L.S.1
Ziesmer, S.C.2
Yang, Z.Z.3
Secreto, F.J.4
Gertz, M.A.5
Novak, A.J.6
-
47
-
-
19944432984
-
Sonic hedgehog is produced by follicular dendritic cells and protects germinal center B cells from apoptosis
-
Sacedon R, Diez B, Nunez V, Hernandez-Lopez C, Gutierrez-Frias C, Cejalvo T et al. Sonic hedgehog is produced by follicular dendritic cells and protects germinal center B cells from apoptosis. J Immunol 2005; 174: 1456-1461.
-
(2005)
J Immunol
, vol.174
, pp. 1456-1461
-
-
Sacedon, R.1
Diez, B.2
Nunez, V.3
Hernandez-Lopez, C.4
Gutierrez-Frias, C.5
Cejalvo, T.6
-
48
-
-
34547683699
-
Essential role of stromally induced hedgehog signaling in B-cell malignancies
-
Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007; 13: 944-951.
-
(2007)
Nat Med
, vol.13
, pp. 944-951
-
-
Dierks, C.1
Grbic, J.2
Zirlik, K.3
Beigi, R.4
Englund, N.P.5
Guo, G.R.6
-
49
-
-
84879165722
-
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma
-
Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK et al. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood 2012; 120: 5002-5013.
-
(2012)
Blood
, vol.120
, pp. 5002-5013
-
-
Blotta, S.1
Jakubikova, J.2
Calimeri, T.3
Roccaro, A.M.4
Amodio, N.5
Azab, A.K.6
-
50
-
-
70349577375
-
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: A therapeutic target
-
Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell 2009; 16: 309-323.
-
(2009)
Cancer Cell
, vol.16
, pp. 309-323
-
-
Chauhan, D.1
Singh, A.V.2
Brahmandam, M.3
Carrasco, R.4
Bandi, M.5
Hideshima, T.6
-
51
-
-
84867606040
-
Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-cell lymphomas
-
Zhang X, Zhao X, Fiskus W, Lin J, Lwin T, Rao R et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell 2012; 22: 506-523.
-
(2012)
Cancer Cell
, vol.22
, pp. 506-523
-
-
Zhang, X.1
Zhao, X.2
Fiskus, W.3
Lin, J.4
Lwin, T.5
Rao, R.6
-
52
-
-
84892615509
-
C-MYC-miRNA circuitry: A central regulator of aggressive B-cell malignancies
-
Tao J, Zhao X, Tao J. c-MYC-miRNA circuitry: a central regulator of aggressive B-cell malignancies. Cell Cycle 2014; 13: 191-198.
-
(2014)
Cell Cycle
, vol.13
, pp. 191-198
-
-
Tao, J.1
Zhao, X.2
Tao, J.3
-
53
-
-
80052955256
-
BET bromodomain inhibition as a therapeutic strategy to target c-Myc
-
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011; 146: 904-917.
-
(2011)
Cell
, vol.146
, pp. 904-917
-
-
Delmore, J.E.1
Issa, G.C.2
Lemieux, M.E.3
Rahl, P.B.4
Shi, J.5
Jacobs, H.M.6
-
54
-
-
77955992756
-
STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer
-
Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010; 39: 493-506.
-
(2010)
Mol Cell
, vol.39
, pp. 493-506
-
-
Iliopoulos, D.1
Jaeger, S.A.2
Hirsch, H.A.3
Bulyk, M.L.4
Struhl, K.5
-
55
-
-
47149085266
-
Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB
-
Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Bjorkstrand B et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 2008; 111: 4617-4626.
-
(2008)
Blood
, vol.111
, pp. 4617-4626
-
-
Yu, L.1
Mohamed, A.J.2
Simonson, O.E.3
Vargas, L.4
Blomberg, K.E.5
Bjorkstrand, B.6
-
56
-
-
77953090345
-
CXCL12 (SDF-1)/CXCR4 pathway in cancer
-
Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010; 16: 2927-2931.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 2927-2931
-
-
Teicher, B.A.1
Fricker, S.P.2
-
57
-
-
33344464945
-
CXCR4: A key receptor in the crosstalk between tumor cells and their microenvironment
-
Burger JA, Kipps TJ. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006; 107: 1761-1767.
-
(2006)
Blood
, vol.107
, pp. 1761-1767
-
-
Burger, J.A.1
Kipps, T.J.2
-
58
-
-
84865176364
-
The B-cell receptor signaling pathway as a therapeutic target in CLL
-
Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012; 120: 1175-1184.
-
(2012)
Blood
, vol.120
, pp. 1175-1184
-
-
Woyach, J.A.1
Johnson, A.J.2
Byrd, J.C.3
-
59
-
-
47249129069
-
SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia
-
Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008; 112: 150-158.
-
(2008)
Blood
, vol.112
, pp. 150-158
-
-
Ngo, H.T.1
Leleu, X.2
Lee, J.3
Jia, X.4
Melhem, M.5
Runnels, J.6
-
60
-
-
49649087786
-
Regulation of integrin activation through the B-cell receptor
-
Arana E, Harwood NE, Batista FD. Regulation of integrin activation through the B-cell receptor. J Cell Sci 2008; 121: 2279-2286.
-
(2008)
J Cell Sci
, vol.121
, pp. 2279-2286
-
-
Arana, E.1
Harwood, N.E.2
Batista, F.D.3
-
61
-
-
67650458526
-
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
-
Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009; 69: 5424-5432.
-
(2009)
Cancer Res
, vol.69
, pp. 5424-5432
-
-
Buchner, M.1
Fuchs, S.2
Prinz, G.3
Pfeifer, D.4
Bartholome, K.5
Burger, M.6
-
62
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010; 115: 2578-2585.
-
(2010)
Blood
, vol.115
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
Johnston, P.B.4
Vose, J.M.5
Lacasce, A.6
-
63
-
-
84871806385
-
Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
-
Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
-
(2013)
J Clin Oncol
, vol.31
, pp. 88-94
-
-
Advani, R.H.1
Buggy, J.J.2
Sharman, J.P.3
Smith, S.M.4
Boyd, T.E.5
Grant, B.6
-
64
-
-
78751553221
-
CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
-
Lannutti BJ, Meadows SA, Herman SE, Kashishian A, Steiner B, Johnson AJ et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011; 117: 591-594.
-
(2011)
Blood
, vol.117
, pp. 591-594
-
-
Lannutti, B.J.1
Meadows, S.A.2
Herman, S.E.3
Kashishian, A.4
Steiner, B.5
Johnson, A.J.6
-
65
-
-
77954680142
-
Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways
-
Stein R, Gupta P, Chen X, Cardillo TM, Furman RR, Chen S et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways. Blood 2010; 115: 5180-5190.
-
(2010)
Blood
, vol.115
, pp. 5180-5190
-
-
Stein, R.1
Gupta, P.2
Chen, X.3
Cardillo, T.M.4
Furman, R.R.5
Chen, S.6
-
66
-
-
2642520461
-
Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment
-
Du W, Hattori Y, Hashiguchi A, Kondoh K, Hozumi N, Ikeda Y et al. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment. Pathol Int 2004; 54: 285-294.
-
(2004)
Pathol Int
, vol.54
, pp. 285-294
-
-
Du, W.1
Hattori, Y.2
Hashiguchi, A.3
Kondoh, K.4
Hozumi, N.5
Ikeda, Y.6
-
67
-
-
27644431763
-
Angiogenesis in malignant lymphoma
-
Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005; 17: 611-616.
-
(2005)
Curr Opin Oncol
, vol.17
, pp. 611-616
-
-
Koster, A.1
Raemaekers, J.M.2
-
68
-
-
0142151228
-
Expression of VEGF and its receptors by myeloma cells
-
Kumar S, Witzig TE, Timm M, Haug J, Wellik L, Fonseca R et al. Expression of VEGF and its receptors by myeloma cells. Leukemia 2003; 17: 2025-2031.
-
(2003)
Leukemia
, vol.17
, pp. 2025-2031
-
-
Kumar, S.1
Witzig, T.E.2
Timm, M.3
Haug, J.4
Wellik, L.5
Fonseca, R.6
-
69
-
-
0037396605
-
Thalidomide as initial therapy for early-stage myeloma
-
Rajkumar SV, Gertz MA, Lacy MQ, Dispenzieri A, Fonseca R, Geyer SM et al. Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
-
(2003)
Leukemia
, vol.17
, pp. 775-779
-
-
Rajkumar, S.V.1
Gertz, M.A.2
Lacy, M.Q.3
Dispenzieri, A.4
Fonseca, R.5
Geyer, S.M.6
-
70
-
-
80053483270
-
Targeting the tumor microenvironment: Focus on angiogenesis
-
Fan F, Schimming A, Jaeger D, Podar K. Targeting the tumor microenvironment: focus on angiogenesis. J Oncol 2012; 2012: 281261.
-
(2012)
J Oncol
, vol.2012
, pp. 281261
-
-
Fan, F.1
Schimming, A.2
Jaeger, D.3
Podar, K.4
-
71
-
-
84858312362
-
Microenvironment-centred dynamics in aggressive B-cell lymphomas
-
Cacciatore M, Guarnotta C, Calvaruso M, Sangaletti S, Florena AM, Franco V et al. Microenvironment-centred dynamics in aggressive B-cell lymphomas. Adv Hematol 2012; 2012: 138079.
-
(2012)
Adv Hematol
, vol.2012
, pp. 138079
-
-
Cacciatore, M.1
Guarnotta, C.2
Calvaruso, M.3
Sangaletti, S.4
Florena, A.M.5
Franco, V.6
-
72
-
-
33947310737
-
Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies
-
Podar K, Anderson KC. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle 2007; 6: 538-542.
-
(2007)
Cell Cycle
, vol.6
, pp. 538-542
-
-
Podar, K.1
Anderson, K.C.2
-
73
-
-
79958859696
-
Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone
-
Nyman JS, Lynch CC, Perrien DS, Thiolloy S, O'Quinn EC, Patil CA et al. Differential effects between the loss of MMP-2 and MMP-9 on structural and tissue-level properties of bone. J Bone Miner Res 2011; 26: 1252-1260.
-
(2011)
J Bone Miner Res
, vol.26
, pp. 1252-1260
-
-
Nyman, J.S.1
Lynch, C.C.2
Perrien, D.S.3
Thiolloy, S.4
O'Quinn, E.C.5
Patil, C.A.6
-
74
-
-
84884170348
-
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes
-
Ruan J, Luo M, Wang C, Fan L, Yang SN, Cardenas M et al. Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood 2013; 121: 5192-5202.
-
(2013)
Blood
, vol.121
, pp. 5192-5202
-
-
Ruan, J.1
Luo, M.2
Wang, C.3
Fan, L.4
Yang, S.N.5
Cardenas, M.6
-
75
-
-
84874259978
-
Stromal cell contribution to human follicular lymphoma pathogenesis
-
Mourcin F, Pangault C, Amin-Ali R, Ame-Thomas P, Tarte K. Stromal cell contribution to human follicular lymphoma pathogenesis. Front Immunol 2012; 3: 280.
-
(2012)
Front Immunol
, vol.3
, pp. 280
-
-
Mourcin, F.1
Pangault, C.2
Amin-Ali, R.3
Ame-Thomas, P.4
Tarte, K.5
-
76
-
-
57149089307
-
Stromal gene signatures in large-B-cell lymphomas
-
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-2323.
-
(2008)
N Engl J Med
, vol.359
, pp. 2313-2323
-
-
Lenz, G.1
Wright, G.2
Dave, S.S.3
Xiao, W.4
Powell, J.5
Zhao, H.6
-
77
-
-
84856485572
-
The immune microenvironment of myeloma
-
Noonan K, Borrello I. The immune microenvironment of myeloma. Cancer Microenviron 2011; 4: 313-323.
-
(2011)
Cancer Microenviron
, vol.4
, pp. 313-323
-
-
Noonan, K.1
Borrello, I.2
-
78
-
-
19944428222
-
Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment
-
Glas AM, Kersten MJ, Delahaye LJ, Witteveen AT, Kibbelaar RE, Velds A et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301-307.
-
(2005)
Blood
, vol.105
, pp. 301-307
-
-
Glas, A.M.1
Kersten, M.J.2
Delahaye, L.J.3
Witteveen, A.T.4
Kibbelaar, R.E.5
Velds, A.6
-
79
-
-
84890531605
-
Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation
-
Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A et al. Follicular lymphoma cells induce changes in T-cell gene expression and function: potential impact on survival and risk of transformation. J Clin Oncol 2013; 31: 2654-2661.
-
(2013)
J Clin Oncol
, vol.31
, pp. 2654-2661
-
-
Kiaii, S.1
Clear, A.J.2
Ramsay, A.G.3
Davies, D.4
Sangaralingam, A.5
Lee, A.6
-
80
-
-
33645286546
-
Regulatory T cells, tumour immunity and immunotherapy
-
Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307.
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 295-307
-
-
Zou, W.1
-
81
-
-
58149376998
-
Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells
-
Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer 2009; 124: 239-244.
-
(2009)
Int J Cancer
, vol.124
, pp. 239-244
-
-
Ai, W.Z.1
Hou, J.Z.2
Zeiser, R.3
Czerwinski, D.4
Negrin, R.S.5
Levy, R.6
-
82
-
-
0037364804
-
Natural versus adaptive regulatory T cells
-
Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3: 253-257.
-
(2003)
Nat Rev Immunol
, vol.3
, pp. 253-257
-
-
Bluestone, J.A.1
Abbas, A.K.2
-
83
-
-
55949108741
-
Inflammatory cells and immune microenvironment in malignant lymphoma
-
de Jong D, Enblad G. Inflammatory cells and immune microenvironment in malignant lymphoma. J Intern Med 2008; 264: 528-536.
-
(2008)
J Intern Med
, vol.264
, pp. 528-536
-
-
De Jong, D.1
Enblad, G.2
-
85
-
-
34548436603
-
Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation
-
Mueller CG, Boix C, Kwan WH, Daussy C, Fournier E, Fridman WH et al. Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation. J Leuk Biol 2007; 82: 567-575.
-
(2007)
J Leuk Biol
, vol.82
, pp. 567-575
-
-
Mueller, C.G.1
Boix, C.2
Kwan, W.H.3
Daussy, C.4
Fournier, E.5
Fridman, W.H.6
-
87
-
-
84875442375
-
Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow
-
Ramachandran IR, Martner A, Pisklakova A, Condamine T, Chase T, Vogl T et al. Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow. J Immunol 2013; 190: 3815-3823.
-
(2013)
J Immunol
, vol.190
, pp. 3815-3823
-
-
Ramachandran, I.R.1
Martner, A.2
Pisklakova, A.3
Condamine, T.4
Chase, T.5
Vogl, T.6
-
88
-
-
84879452593
-
Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans
-
Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 2013; 121: 2975-2987.
-
(2013)
Blood
, vol.121
, pp. 2975-2987
-
-
Gorgun, G.T.1
Whitehill, G.2
Anderson, J.L.3
Hideshima, T.4
Maguire, C.5
Laubach, J.6
-
90
-
-
84869209212
-
Stemness of B-cell progenitors in multiple myeloma bone marrow
-
Boucher K, Parquet N, Widen R, Shain K, Baz R, Alsina M et al. Stemness of B-cell progenitors in multiple myeloma bone marrow. Clin Cancer Res 2012; 18: 6155-6168.
-
(2012)
Clin Cancer Res
, vol.18
, pp. 6155-6168
-
-
Boucher, K.1
Parquet, N.2
Widen, R.3
Shain, K.4
Baz, R.5
Alsina, M.6
-
91
-
-
0036794974
-
Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors
-
Pilarski LM, Belch AR. Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitors. Clin Cancer Res 2002; 8: 3198-3204.
-
(2002)
Clin Cancer Res
, vol.8
, pp. 3198-3204
-
-
Pilarski, L.M.1
Belch, A.R.2
-
92
-
-
0346100567
-
Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors
-
Cozzio A, Passegue E, Ayton PM, Karsunky H, Cleary ML, Weissman IL. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev 2003; 17: 3029-3035.
-
(2003)
Genes Dev
, vol.17
, pp. 3029-3035
-
-
Cozzio, A.1
Passegue, E.2
Ayton, P.M.3
Karsunky, H.4
Cleary, M.L.5
Weissman, I.L.6
-
93
-
-
3943088431
-
Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML
-
Jamieson CH, Ailles LE, Dylla SJ, Muijtjens M, Jones C, Zehnder JL et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blastcrisis CML. N Engl J Med 2004; 351: 657-667.
-
(2004)
N Engl J Med
, vol.351
, pp. 657-667
-
-
Jamieson, C.H.1
Ailles, L.E.2
Dylla, S.J.3
Muijtjens, M.4
Jones, C.5
Zehnder, J.L.6
-
95
-
-
44749086557
-
Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets
-
Rappa G, Mercapide J, Anzanello F, Prasmickaite L, Xi Y, Ju J et al. Growth of cancer cell lines under stem cell-like conditions has the potential to unveil therapeutic targets. Exp Cell Res 2008; 314: 2110-2122.
-
(2008)
Exp Cell Res
, vol.314
, pp. 2110-2122
-
-
Rappa, G.1
Mercapide, J.2
Anzanello, F.3
Prasmickaite, L.4
Xi, Y.5
Ju, J.6
-
96
-
-
8644219660
-
C-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation
-
Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev 2004; 18: 2747-2763.
-
(2004)
Genes Dev
, vol.18
, pp. 2747-2763
-
-
Wilson, A.1
Murphy, M.J.2
Oskarsson, T.3
Kaloulis, K.4
Bettess, M.D.5
Oser, G.M.6
-
97
-
-
0035793794
-
Telomerase activity in plasma cell dyscrasias
-
Xu D, Zheng C, Bergenbrant S, Holm G, Bjorkholm M, Yi Q et al. Telomerase activity in plasma cell dyscrasias. Br J Cancer 2001; 84: 621-625.
-
(2001)
Br J Cancer
, vol.84
, pp. 621-625
-
-
Xu, D.1
Zheng, C.2
Bergenbrant, S.3
Holm, G.4
Bjorkholm, M.5
Yi, Q.6
-
98
-
-
0842289983
-
Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma
-
Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC et al. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res 2004; 10: 770-776.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 770-776
-
-
Shammas, M.A.1
Shmookler Reis, R.J.2
Li, C.3
Koley, H.4
Hurley, L.H.5
Anderson, K.C.6
-
99
-
-
79952284127
-
Hallmarks of cancer: The next generation
-
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674.
-
(2011)
Cell
, vol.144
, Issue.5
, pp. 646-674
-
-
Hanahan, D.1
Weinberg, R.A.2
-
100
-
-
66149150580
-
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy
-
Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood 2009; 113: 4341-4351.
-
(2009)
Blood
, vol.113
, pp. 4341-4351
-
-
Azab, A.K.1
Runnels, J.M.2
Pitsillides, C.3
Moreau, A.S.4
Azab, F.5
Leleu, X.6
-
101
-
-
84855458019
-
Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists
-
Hu Y, Gale M, Shields J, Garron C, Swistak M, Nguyen TH et al. Enhancement of the anti-tumor activity of therapeutic monoclonal antibodies by CXCR4 antagonists. Leuk Lymphoma 2012; 53: 130-138.
-
(2012)
Leuk Lymphoma
, vol.53
, pp. 130-138
-
-
Hu, Y.1
Gale, M.2
Shields, J.3
Garron, C.4
Swistak, M.5
Nguyen, T.H.6
-
102
-
-
84857478229
-
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia
-
O'Callaghan K, Lee L, Nguyen N, Hsieh MY, Kaneider NC, Klein AK et al. Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood 2012; 119: 1717-1725.
-
(2012)
Blood
, vol.119
, pp. 1717-1725
-
-
O'Callaghan, K.1
Lee, L.2
Nguyen, N.3
Hsieh, M.Y.4
Kaneider, N.C.5
Klein, A.K.6
-
103
-
-
80052570271
-
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance
-
Mraz M, Zent CS, Church AK, Jelinek DF, Wu X, Pospisilova S et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011; 155: 53-64.
-
(2011)
Br J Haematol
, vol.155
, pp. 53-64
-
-
Mraz, M.1
Zent, C.S.2
Church, A.K.3
Jelinek, D.F.4
Wu, X.5
Pospisilova, S.6
-
104
-
-
83355163335
-
Acquisition of resistance toward HYD1 correlates with a reduction in cleaved alpha4 integrin expression and a compromised CAM-DR phenotype
-
Emmons MF, Gebhard AW, Nair RR, Baz R, McLaughlin ML, Cress AE et al. Acquisition of resistance toward HYD1 correlates with a reduction in cleaved alpha4 integrin expression and a compromised CAM-DR phenotype. Mol Cancer Ther 2011; 10: 2257-2266.
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 2257-2266
-
-
Emmons, M.F.1
Gebhard, A.W.2
Nair, R.R.3
Baz, R.4
McLaughlin, M.L.5
Cress, A.E.6
-
105
-
-
84866324411
-
Impact of lenalidomide on the functional properties of human mesenchymal stromal cells
-
Wobus M, Benath G, Ferrer RA, Wehner R, Schmitz M, Hofbauer LC et al. Impact of lenalidomide on the functional properties of human mesenchymal stromal cells. Exp Hematol 2012; 40: 867-876.
-
(2012)
Exp Hematol
, vol.40
, pp. 867-876
-
-
Wobus, M.1
Benath, G.2
Ferrer, R.A.3
Wehner, R.4
Schmitz, M.5
Hofbauer, L.C.6
-
106
-
-
84861209840
-
RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans
-
Troeger A, Johnson AJ, Wood J, Blum WG, Andritsos LA, Byrd JC et al. RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood 2012; 119: 4708-4718.
-
(2012)
Blood
, vol.119
, pp. 4708-4718
-
-
Troeger, A.1
Johnson, A.J.2
Wood, J.3
Blum, W.G.4
Andritsos, L.A.5
Byrd, J.C.6
-
107
-
-
84865585752
-
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
-
Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood 2012; 120: 1877-1887.
-
(2012)
Blood
, vol.120
, pp. 1877-1887
-
-
Tai, Y.T.1
Chang, B.Y.2
Kong, S.Y.3
Fulciniti, M.4
Yang, G.5
Calle, Y.6
-
108
-
-
84863781222
-
Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration
-
Hoellenriegel J, Coffey GP, Sinha U, Pandey A, Sivina M, Ferrajoli A et al. Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration. Leukemia 2012; 26: 1576-1583.
-
(2012)
Leukemia
, vol.26
, pp. 1576-1583
-
-
Hoellenriegel, J.1
Coffey, G.P.2
Sinha, U.3
Pandey, A.4
Sivina, M.5
Ferrajoli, A.6
-
109
-
-
84905816538
-
Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the bruton tyrosine kinase (Btk) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM)
-
Vij R, Chang BY, Berdeja JG, Huff CA, Lendvai N, Tai YT et al. Early changes in cytokines, chemokines and indices of bone metabolism in a phase 2 study of the bruton tyrosine kinase (Btk) inhibitor, ibrutinib (PCI-32765) in patients with relapsed or relapsed/refractory multiple myeloma (MM). ASH Annu Meeting Abstr 2012; 120: 4039.
-
(2012)
ASH Annu Meeting Abstr
, vol.120
, pp. 4039
-
-
Vij, R.1
Chang, B.Y.2
Berdeja, J.G.3
Huff, C.A.4
Lendvai, N.5
Tai, Y.T.6
-
110
-
-
84879748062
-
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.
-
(2013)
N Engl J Med
, vol.369
, pp. 32-42
-
-
Byrd, J.C.1
Furman, R.R.2
Coutre, S.E.3
Flinn, I.W.4
Burger, J.A.5
Blum, K.A.6
-
111
-
-
84884523966
-
Ibrutinib in relapsed chronic lymphocytic leukemia
-
Byrd JC, O'Brien S, James DF. Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 1278-1279.
-
(2013)
N Engl J Med
, vol.369
, pp. 1278-1279
-
-
Byrd, J.C.1
O'Brien, S.2
James, D.F.3
-
112
-
-
84868211774
-
Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape
-
Burger JA. Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 2012; 24: 643-649.
-
(2012)
Curr Opin Oncol
, vol.24
, pp. 643-649
-
-
Burger, J.A.1
-
113
-
-
84902470158
-
PI3K in cancer-stroma interactions: Bad in seed and ugly in soil
-
Hirsch E, Ciraolo E, Franco I, Ghigo A, Martini M. PI3K in cancer-stroma interactions: bad in seed and ugly in soil. Oncogene 2013; 33: 3083-3090.
-
(2013)
Oncogene
, vol.33
, pp. 3083-3090
-
-
Hirsch, E.1
Ciraolo, E.2
Franco, I.3
Ghigo, A.4
Martini, M.5
-
114
-
-
84901712964
-
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia
-
Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014; 123: 3390-3397.
-
(2014)
Blood
, vol.123
, pp. 3390-3397
-
-
Brown, J.R.1
Byrd, J.C.2
Coutre, S.E.3
Benson, D.M.4
Flinn, I.W.5
Wagner-Johnston, N.D.6
-
115
-
-
84901703641
-
Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma
-
Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014; 123: 3406-3413.
-
(2014)
Blood
, vol.123
, pp. 3406-3413
-
-
Flinn, I.W.1
Kahl, B.S.2
Leonard, J.P.3
Furman, R.R.4
Brown, J.R.5
Byrd, J.C.6
-
116
-
-
84896693794
-
PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma
-
Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014; 370: 1008-1018.
-
(2014)
N Engl J Med
, vol.370
, pp. 1008-1018
-
-
Gopal, A.K.1
Kahl, B.S.2
De Vos, S.3
Wagner-Johnston, N.D.4
Schuster, S.J.5
Jurczak, W.J.6
-
117
-
-
84901724050
-
A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
-
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014; 123: 3398-3405.
-
(2014)
Blood
, vol.123
, pp. 3398-3405
-
-
Kahl, B.S.1
Spurgeon, S.E.2
Furman, R.R.3
Flinn, I.W.4
Coutre, S.E.5
Brown, J.R.6
-
118
-
-
84868633053
-
Treatmentinduced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B
-
Sun Y, Campisi J, Higano C, Beer TM, Porter P, Coleman I et al. Treatmentinduced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med 2012; 18: 1359-1368.
-
(2012)
Nat Med
, vol.18
, pp. 1359-1368
-
-
Sun, Y.1
Campisi, J.2
Higano, C.3
Beer, T.M.4
Porter, P.5
Coleman, I.6
-
119
-
-
84868640245
-
The tumor microenvironment controls drug sensitivity
-
Ostman A. The tumor microenvironment controls drug sensitivity. Nat Med 2012; 18: 1332-1334.
-
(2012)
Nat Med
, vol.18
, pp. 1332-1334
-
-
Ostman, A.1
-
120
-
-
84872387409
-
Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo
-
Lutzny G, Kocher T, Schmidt-Supprian M, Rudelius M, Klein-Hitpass L, Finch AJ et al. Protein kinase c-beta-dependent activation of NF-kappaB in stromal cells is indispensable for the survival of chronic lymphocytic leukemia B cells in vivo. Cancer Cell 2013; 23: 77-92.
-
(2013)
Cancer Cell
, vol.23
, pp. 77-92
-
-
Lutzny, G.1
Kocher, T.2
Schmidt-Supprian, M.3
Rudelius, M.4
Klein-Hitpass, L.5
Finch, A.J.6
|